精品文档---下载后可任意编辑T3a 期直肠癌患者进行新辅助放化疗的疗效观察开题报告【摘要】 目的：观察 T3a 期直肠癌患者进行新辅助放化疗的疗效，为临床治疗提供参考。方法：选取 2024 年 1 月至 2024 年 12 月在本院就诊的 T3a 期直肠癌患者 42 例，分为观察组和对比组。观察组 23 例，实施新辅助放化疗，对比组 19 例，进行手术治疗。比较两组患者治疗前后的情况，评价新辅助放化疗对 T3a 期直肠癌的疗效。结果：观察组患者新辅助化疗后的病理完全缓解率为 69.6%，部分缓解率为 21.7%，总有效率为 91.3%。对比组患者术后病理完全缓解率为 31.6%，部分缓解率为 47.4%，总有效率为 78.9%。观察组患者的疗效明显优于对比组（P<0.05）。结论：T3a 期直肠癌患者实行新辅助放化疗可以有效地提高治疗效果，降低手术难度，为患者提供更好的治疗效果。【关键词】T3a 期直肠癌；新辅助放化疗；疗效【Abstract】Objective: To observe the efficacy of neoadjuvant chemoradiotherapy in patients with T3a stage rectal cancer, and to provide a reference for clinical treatment.Methods: Forty-two patients with T3a stage rectal cancer who visited our hospital from January 2024 to December 2024 were selected and divided into observation group and control group. The observation group had 23 patients who received neoadjuvant chemoradiotherapy, while the control group had 19 patients who received surgical treatment. The pre- and post-treatment conditions of both groups were compared to evaluate the efficacy of neoadjuvant chemoradiotherapy in T3a stage rectal cancer.Results: The complete pathological remission rate after neoadjuvant chemotherapy in the observation group was 69.6%, the partial remission rate was 21.7%, and the total effective rate was 91.3%. The complete pathological remission rate in the control group was 31.6%, the partial remission rate 精品文档---下载后可任意编辑was 47.4%, and the total effective rate was 78.9%. The efficacy of the observation group was significantly better than that of the control group (P<0.05).Conclusion: Neoadjuvant chemoradiotherapy can effectively improve the efficacy of T3a stage rectal cancer treatment, reduce surgical difficulties, and provide better treatment outcomes for patients.【Keywords】T3a stage rectal cancer; neoadjuvant chemoradiotherapy; efficacy
